Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCSK9 Sponsors May See Opportunity In Off-Label Promotion Court Case

Executive Summary

With robust data on LDL-cholesterol lowering, sponsors of Praluent and Repatha could approach FDA with statements about broader use in lower risk patients, even before cardiovascular outcomes trials complete.

Advertisement

Related Content

Praluent Coverage: Being First May Not Matter As Payers Await Repatha
Reading The Praluent Tea Leaves Ahead Of Repatha's Approval
FDA Makes It Formal, Rescinds SPA For Amarin’s ANCHOR Study

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057066

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel